+
データを開く
-
基本情報
登録情報 | データベース: PDB / ID: 6jht | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
タイトル | The cryo-EM structure of HAV bound to a neutralizing antibody-F9 | ||||||||||||
![]() |
| ||||||||||||
![]() | VIRUS / Icosahedral symmetry / neutralizing antibody / HAV / complex | ||||||||||||
機能・相同性 | ![]() host cell mitochondrial outer membrane / symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of MAVS activity / ribonucleoside triphosphate phosphatase activity / picornain 3C / T=pseudo3 icosahedral viral capsid / host multivesicular body / host cell cytoplasmic vesicle membrane / nucleoside-triphosphate phosphatase / channel activity / monoatomic ion transmembrane transport ...host cell mitochondrial outer membrane / symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of MAVS activity / ribonucleoside triphosphate phosphatase activity / picornain 3C / T=pseudo3 icosahedral viral capsid / host multivesicular body / host cell cytoplasmic vesicle membrane / nucleoside-triphosphate phosphatase / channel activity / monoatomic ion transmembrane transport / RNA helicase activity / symbiont entry into host cell / RNA-directed RNA polymerase / cysteine-type endopeptidase activity / viral RNA genome replication / RNA-directed RNA polymerase activity / DNA-templated transcription / : / virion attachment to host cell / structural molecule activity / proteolysis / RNA binding / ATP binding / membrane 類似検索 - 分子機能 | ||||||||||||
生物種 | ![]() | ||||||||||||
手法 | 電子顕微鏡法 / 単粒子再構成法 / クライオ電子顕微鏡法 / 解像度: 3.79 Å | ||||||||||||
![]() | Cao, L. / Liu, P. / Yang, P. / Gao, Q. / Li, H. / Sun, Y. / Zhu, L. / Lin, J. / Su, D. / Rao, Z. / Wang, X. | ||||||||||||
資金援助 | ![]()
| ||||||||||||
![]() | ![]() タイトル: Structural basis for neutralization of hepatitis A virus informs a rational design of highly potent inhibitors. 著者: Lei Cao / Pi Liu / Pan Yang / Qiang Gao / Hong Li / Yao Sun / Ling Zhu / Jianping Lin / Dan Su / Zihe Rao / Xiangxi Wang / ![]() 要旨: Hepatitis A virus (HAV), an enigmatic and ancient pathogen, is a major causative agent of acute viral hepatitis worldwide. Although there are effective vaccines, antivirals against HAV infection are ...Hepatitis A virus (HAV), an enigmatic and ancient pathogen, is a major causative agent of acute viral hepatitis worldwide. Although there are effective vaccines, antivirals against HAV infection are still required, especially during fulminant hepatitis outbreaks. A more in-depth understanding of the antigenic characteristics of HAV and the mechanisms of neutralization could aid in the development of rationally designed antiviral drugs targeting HAV. In this paper, 4 new antibodies-F4, F6, F7, and F9-are reported that potently neutralize HAV at 50% neutralizing concentration values (neut50) ranging from 0.1 nM to 0.85 nM. High-resolution cryo-electron microscopy (cryo-EM) structures of HAV bound to F4, F6, F7, and F9, together with results of our previous studies on R10 fragment of antigen binding (Fab)-HAV complex, shed light on the locations and nature of the epitopes recognized by the 5 neutralizing monoclonal antibodies (NAbs). All the epitopes locate within the same patch and are highly conserved. The key structure-activity correlates based on the antigenic sites have been established. Based on the structural data of the single conserved antigenic site and key structure-activity correlates, one promising drug candidate named golvatinib was identified by in silico docking studies. Cell-based antiviral assays confirmed that golvatinib is capable of blocking HAV infection effectively with a 50% inhibitory concentration (IC50) of approximately 1 μM. These results suggest that the single conserved antigenic site from complete HAV capsid is a good antiviral target and that golvatinib could function as a lead compound for anti-HAV drug development. | ||||||||||||
履歴 |
|
-
構造の表示
ムービー |
![]() |
---|---|
構造ビューア | 分子: ![]() ![]() |
-
ダウンロードとリンク
-
ダウンロード
PDBx/mmCIF形式 | ![]() | 212 KB | 表示 | ![]() |
---|---|---|---|---|
PDB形式 | ![]() | 167.7 KB | 表示 | ![]() |
PDBx/mmJSON形式 | ![]() | ツリー表示 | ![]() | |
その他 | ![]() |
-検証レポート
文書・要旨 | ![]() | 889.7 KB | 表示 | ![]() |
---|---|---|---|---|
文書・詳細版 | ![]() | 897.1 KB | 表示 | |
XML形式データ | ![]() | 36.5 KB | 表示 | |
CIF形式データ | ![]() | 55.4 KB | 表示 | |
アーカイブディレクトリ | ![]() ![]() | HTTPS FTP |
-関連構造データ
-
リンク
-
集合体
登録構造単位 | ![]()
|
---|---|
1 | ![]()
| x 60
2 |
|
3 | ![]()
| x 5
4 | ![]()
| x 6
5 | ![]()
|
対称性 | 点対称性: (シェーンフリース記号: I (正20面体型対称)) |
-
要素
#1: タンパク質 | 分子量: 30820.629 Da / 分子数: 1 / 由来タイプ: 天然 由来: (天然) ![]() 参照: UniProt: P08617*PLUS |
---|---|
#2: タンパク質 | 分子量: 24898.172 Da / 分子数: 1 / 由来タイプ: 天然 由来: (天然) ![]() 参照: UniProt: P08617*PLUS |
#3: タンパク質 | 分子量: 27835.693 Da / 分子数: 1 / 由来タイプ: 天然 由来: (天然) ![]() 参照: UniProt: P08617*PLUS |
#4: 抗体 | 分子量: 23391.775 Da / 分子数: 1 / 由来タイプ: 天然 由来: (天然) ![]() |
#5: 抗体 | 分子量: 23684.768 Da / 分子数: 1 / 由来タイプ: 天然 由来: (天然) ![]() |
Has protein modification | Y |
-実験情報
-実験
実験 | 手法: 電子顕微鏡法 |
---|---|
EM実験 | 試料の集合状態: PARTICLE / 3次元再構成法: 単粒子再構成法 |
-
試料調製
構成要素 |
| ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
由来(天然) |
| ||||||||||||||||||||||||
ウイルスについての詳細 | 中空か: NO / エンベロープを持つか: NO / 単離: SPECIES / タイプ: VIRION | ||||||||||||||||||||||||
緩衝液 | pH: 7 | ||||||||||||||||||||||||
試料 | 包埋: NO / シャドウイング: NO / 染色: NO / 凍結: YES | ||||||||||||||||||||||||
急速凍結 | 凍結剤: ETHANE |
-
電子顕微鏡撮影
実験機器 | ![]() モデル: Titan Krios / 画像提供: FEI Company |
---|---|
顕微鏡 | モデル: FEI TITAN KRIOS |
電子銃 | 電子線源: ![]() |
電子レンズ | モード: BRIGHT FIELD |
撮影 | 電子線照射量: 1.3 e/Å2 フィルム・検出器のモデル: GATAN K2 BASE (4k x 4k) |
-
解析
ソフトウェア | 名称: PHENIX / バージョン: 1.11.1_2575: / 分類: 精密化 | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EMソフトウェア | 名称: PHENIX / カテゴリ: 3次元再構成 | ||||||||||||||||||||||||
CTF補正 | タイプ: NONE | ||||||||||||||||||||||||
3次元再構成 | 解像度: 3.79 Å / 解像度の算出法: FSC 0.143 CUT-OFF / 粒子像の数: 3798 / 対称性のタイプ: POINT | ||||||||||||||||||||||||
拘束条件 |
|